Revelation Biosciences (REVB) Non-Current Assets (2020 - 2026)
Revelation Biosciences (REVB) posted quarterly Non-Current Assets of $771296.0 for Q4 2025, up 1269.2% year-over-year from $56332.0 in Q4 2024, and up 3124.62% quarter-over-quarter from $23919.0 in Q3 2025.
Revelation Biosciences (REVB) Non-Current Assets (2020 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Non-Current Assets for 6 consecutive years, with $771296.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets rose 1269.2% year-over-year to $771296.0; the TTM figure through Dec 2025 stood at $872775.0 (up 204.8% YoY), while the FY2025 annual figure was $771296.0, up 1269.2% from the prior year.
- Non-Current Assets improved to $771296.0 in Q4 2025 per REVB's latest filing, from $23919.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $73.5 million in Q3 2021 and bottomed at $23919.0 in Q3 2025.
- Historically, Non-Current Assets has averaged $11.1 million across 5 years, with a median of $82556.0 in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 99.87% — and 2025, when it soared 1269.2%.
- Revelation Biosciences' Non-Current Assets stood at $130141.0 in 2021, then tumbled by 30.74% to $90133.0 in 2022, then fell by 27.79% to $65084.0 in 2023, then slipped by 13.45% to $56332.0 in 2024, then jumped by 1269.2% to $771296.0 in 2025.
- Business Quant data shows REVB's Non-Current Assets at $771296.0 in Q4 2025, $23919.0 in Q3 2025, and $35170.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 18.06 Bn |
| 10 | Revelation Biosciences | 4.13 Mn | -7.37 Mn | - | 813,416.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 813,416.00 |
| Dec 31, 2025 | 771,296.00 |
| Sep 30, 2025 | 23,919.00 |
| Jun 30, 2025 | 35,170.00 |
| Mar 31, 2025 | 42,390.00 |
| Dec 31, 2024 | 56,332.00 |
| Sep 30, 2024 | 81,242.00 |
| Jun 30, 2024 | 70,774.00 |
| Mar 31, 2024 | 77,994.00 |
| Dec 31, 2023 | 65,084.00 |
| Sep 30, 2023 | 71,346.00 |
| Jun 30, 2023 | 77,608.00 |
| Mar 31, 2023 | 83,870.00 |
| Dec 31, 2022 | 90,133.00 |
| Sep 30, 2022 | 96,395.00 |
| Jun 30, 2022 | 102,657.00 |
| Mar 31, 2022 | 108,919.00 |
| Dec 31, 2021 | 130,141.00 |
| Sep 30, 2021 | 73.52 Mn |
| Jun 30, 2021 | 73.51 Mn |